Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Eledon Pharmaceuticals, Inc. | nvus-10k_20171231.htm |
| EX-32.2 - EX-32.2 - Eledon Pharmaceuticals, Inc. | nvus-ex322_9.htm |
| EX-32.1 - EX-32.1 - Eledon Pharmaceuticals, Inc. | nvus-ex321_8.htm |
| EX-31.2 - EX-31.2 - Eledon Pharmaceuticals, Inc. | nvus-ex312_10.htm |
| EX-31.1 - EX-31.1 - Eledon Pharmaceuticals, Inc. | nvus-ex311_11.htm |
| EX-23.2 - EX-23.2 - Eledon Pharmaceuticals, Inc. | nvus-ex232_148.htm |
| EX-21.1 - EX-21.1 - Eledon Pharmaceuticals, Inc. | nvus-ex211_12.htm |
| EX-10.12 - EX-10.12 - Eledon Pharmaceuticals, Inc. | nvus-ex1012_430.htm |
| EX-10.11 - EX-10.11 - Eledon Pharmaceuticals, Inc. | nvus-ex1011_429.htm |
| EX-10.10 - EX-10.10 - Eledon Pharmaceuticals, Inc. | nvus-ex1010_428.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Forms S-3 (Nos. 333-218949 and 333-207359) and S-8 (Nos. 333-216432, 333-210058, 333-203032, and 333-200413) of our report dated March 30, 2018, with respect to the consolidated financial statements of Novus Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Irvine, California
March 30, 2018